This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: July 25, 2006
Last updated: September 30, 2014
Last verified: September 2014
The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.

Condition Intervention Phase
Vasomotor Symptoms Drug: Estradiol/DRSP (Angeliq, BAY86-4891) Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq® (Drospirenone 2mg and Estradiol 1mg) in Postmenopausal Chinese Women With Vasomotor Symptoms Over Four 28-day Treatment Cycles.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Frequency of hot flushes [ Time Frame: From baseline to week 16 ]
  • Change in intensity of hot flushes [ Time Frame: From baseline to week 16 ]

Secondary Outcome Measures:
  • Change in other climacteric symptoms [ Time Frame: From baseline to week 16 ]
  • Vaginal Bleeding pattern [ Time Frame: From baseline to week 16 ]
  • Global clinical impression [ Time Frame: From baseline to week 16 ]

Enrollment: 249
Study Start Date: May 2006
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1 Drug: Estradiol/DRSP (Angeliq, BAY86-4891)
Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
Placebo Comparator: Arm 2 Drug: Placebo
Same administration.

Detailed Description:
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.

Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chinese postmenopausal women with moderate to severe vasomotor symptoms

Exclusion Criteria:

  • History of steroid hormone dependent malignant disease
  • Known or suspected malignant or premalignant disease
  • Current or history of severe heart, liver, renal, psychiatric disease
  • Hyperlipemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00356447

China, Hubei
Wuhan, Hubei, China, 430032
China, Jiangsu
Nanjing, Jiangsu, China, 210029
China, Shandong
Jinan, Shandong, China, 250012
Beijing, China, 100020
Beijing, China, 100034
Beijing, China, 100083
Beijing, China, 100730
Chongqing, China, 400010
Shanghai, China, 200011
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00356447     History of Changes
Other Study ID Numbers: 91442
309341 ( Other Identifier: Company internal )
Study First Received: July 25, 2006
Last Updated: September 30, 2014

Additional relevant MeSH terms:
Polyestradiol phosphate
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Drospirenone and ethinyl estradiol combination
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Diuretics, Potassium Sparing
Natriuretic Agents processed this record on July 21, 2017